Actemra Campaign Details

Prices listed are the current retail value and may be higher or lower based on availability, size of budget, demand, volatility and additional filters.

  • Actemra lead
    Call for pricing
  • Actemra signed
    Call for pricing

Actemra Criteria

  • Took Actemra for arthritis (RA, SJIA, PJIA) after 2010
  • Suffered from any of the following while on the medication
    • Heart Attack
    • Stroke
    • Congestive Heart Failure
    • Lung Disease
    • Pancreatitis
  • No legal representation

Actemra Additional Information


Genentech (Roche subsidiary)

Generic Name


Treatment for

Rheumatoid and giant cell arthritis drug

Immuncoresponsive drug

Actemra is an immunoresponsive drug (IL-6 receptor inhibitors) that was approved in 2010, and has been linked to heart attacks, strokes, interstitial lung disease, heat failure, acute pancreatitis, brain bleeds and other life threatening complications.

June 2017

A report by identified thousands of adverse event reports submitted to the FDA over the past seven years, and has been linked to at least 1,128 deaths.


The Phase 3 clinical study, GIACTA, showed that serious adverse events occurred in 15% (roughly 1:7) patients using Actemra in the study. Competing L-6 receptor inhibitors such as Humira, Enbrel, and Remicade, contain strong warnings against the above side effects. Actemra does not.


We welcome you to contact Mass Torts USA for more information
about our products and services.